home / stock / otlc / otlc news

OTLC News and Press, Oncotelic Therapeutics Inc From 11/16/21

Stock Information
Company Name: Oncotelic Therapeutics Inc
Stock Symbol: OTLC
Market: OTC
Website: oncotelic.com
Menu
OTLC OTLC Quote OTLC Short OTLC News OTLC Articles OTLC Message Board
Get OTLC Alerts

News, Short Squeeze, Breakout and More Instantly...
OTLC - Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-? Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers

AGOURA HILLS, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, provided an update on ongoing OT-101/IL-2 combination trial (the “Trial”...
OTLC - ONCOTELIC ANNOUNCES UPDATE ON THE OT-101 CLINICAL PROGRAMS INCLUDING C001 COVID STUDY

AGOURA HILLS, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and virology today announced an update on the Phase 2 C001 Covid Study and the O...

OTLC - ONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.

AGOURA HILLS, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ( “ Oncotelic ” or the “ Company ” ) ( OTCQB:OTLC ) , executed an exclusive licensing agreement on September 30, 2021, wit...

OTLC - ONCOTELIC TO ACQUIRE LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.

AGOURA HILLS, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") ( OTCQB:OTLC ) , executed a binding term sheet with Autotelic Inc. to license AL-101 (intranasal apomorphine). Oncotelic intends to develop AL-101 via fast-to...
OTLC - PULMOHEAL(TM)/ ARTIVEDA(TM) IS CLINICALLY ACTIVE AGAINST MILD AND MODERATE COVID-19.

AGOURA HILLS, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (" Oncotelic " or the "Company") (OTCQB:OTLC) , a leading developer of TGF-β therapeutics for oncology and COVID-19, reported today that PulmoHeal TM / ArtiVeda TM has...

OTLC - ONCOTELIC AND GOLDEN MOUNTAIN PARTNERS FORMING A JOINT VENTURE FOR IPO

AGOURA HILLS, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (" Oncotelic " or the "Company") (OTCQB:OTLC) , a leading developer of TGF-β therapeutics for oncology and COVID-19 and Golden Mountain Partners, ( “ GMP ”...

OTLC - Oncotelic closes COVID-19 clinical trial early

Oncotelic Therapeutics ([[OTLC]]) announces that, as of June 11, it has discontinued enrollment in its OT-101 clinical trial in patients with COVID-19.The trial completed randomization of 32 out of 36 patients planned, on an intent to treat basis. “Due to the continuing rise of more se...
OTLC - ONCOTELIC CLOSES COVID-19 CLINICAL TRIAL EARLY.

AGOURA HILLS, California, June 15, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic" or the “Company”), a leading developer of TGF-β therapeutics for oncology, infectious diseases and respiratory health announced that, as of June 11, 20...

OTLC - Oncotelic Joins Chopra Foundation and Heart Foundation of India to Provide Relief for India's Explosive 2nd Wave of Covid.

AGOURA HILLS, California, May 04, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic"), a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health will be working with Chopra Foundation and Heart Care Foundatio...

OTLC - Oncotelic Therapeutics posts positive topline results from COVID-19 trial

Oncotelic Therapeutics ([[OTLC]] -4.6%) posts positive topline data from its COVID-19 clinical trial, ARTI-19, evaluating PulmoHeal against COVID-19 in India.PulmoHeal, which is being developed by Oncotelic in partnership with Windlas Biotech Private, when added to the sta...
Previous 10 Next 10